Raymond Hohl

University Professor of Oncology; Professor of Pharmacology

Raymond Hohl

Huck Affiliations

Links

Most Recent Publications

Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02

Akshita Khosla, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, Christopher Ehmann, David Claxton, Witold Rybka, Jeffrey Sivik, Joseph Mierski, Brooke Silar, Caitlin Vajdic, Raymond Hohl, Hiroko Shike, Shin Mineishi, Kentaro Minagawa, 2024, Trasfusione del Sangue on p. 525-528

Impact of post-transplant cyclophosphamide and splenomegaly on primary graft failure and multi-lineage cytopenia after allogeneic hematopoietic cell transplantation

Emma Zulch, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, Witold Rybka, Christopher Ehmann, Jeffrey Sivik, Jseph Mierski, Brooke Silar, Caitlin Vajdic, Robert Greiner, Valerie Brown, Raymond Hohl, David Claxton, Hiroko Shike, Catharine I. Paules, Shin Mineishi, Kentaro Minagawa, 2024, Leukemia Research

The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma

Emma G. Guare, Cory M. Hale, Jeffrey Sivik, Erik Lehman, Yoshika Inoue, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, David Claxton, Witold Rybka, Raymond Hohl, Shin Mineishi, Kentaro Minagawa, Catharine I. Paules, 2024, Transplant Infectious Disease

RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins

J. S. Weissenrieder, J. D. Weissenkampen, J. L. Reed, M. V. Green, C. Zheng, J. D. Neighbors, D. J. Liu, Raymond J. Hohl, 2022, Scientific Reports

Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma

Emily J. Koubek, Jillian S. Weissenrieder, Luz E. Ortiz, Nnenna Nwogu, Alexander M. Pham, J. Dylan Weissenkampen, Jessie L. Reed, Jeffrey D. Neighbors, Raymond J. Hohl, Hyun Jin Kwun, 2022, Viruses

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios A. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M. Liberati, Hartmut Goldschmidt, Andrew Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria T. Petrucci, Donna Reece, Darrell White, María Victoria Mateos, Ivan Špička, Mihaela Lazaroiu, Jesús Berdeja, Jonathan L. Kaufman, Ying Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham-Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo De Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo M. Carella, Massimo Offidani, Joan Bladé, Luis F. Casado, Heather Oakervee, Victoria Panelli, Luis Meza, Thomas Kühr, Raymond Hohl, 2022, The Lancet Haematology on p. e403-e414

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant

Chenchen Zhao, Matthew Bartock, Bei Jia, Neal Shah, David F. Claxton, Baldeep Wirk, Kevin L. Rakszawski, Myles S. Nickolich, Seema Naik, Witold B. Rybka, Ehmann WCC, W. Christopher C. Ehmann, Raymond J. Hohl, Jessica Valentin, Michelle Bernas-Peterson, Emily Gerber, Michele Zimmerman, Joseph Mierski, Shin Mineishi, Hong Zheng, 2022, Journal of Hematology and Oncology on p. 64

Schweinfurthin induces ICD without ER stress and caspase activation

Ruoheng Zhang, J. D. Neighbors, T. D. Schell, R. J. Hohl, 2022, OncoImmunology

Cytotoxic Effects of the Schweinfurthin Analog 5'-Methylschweinfurthin G in Malignant Plasma Cells

Barbara Manfredi, Jeffrey D. Neighbors, Raymond J. Hohl, 2022, Pharmacology on p. 510-523

Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis

Joseph Cioccio, Kevin Rakszawski, Hong Zheng, Myles Nickolich, Seema Naik, Baldeep Wirk, Witold Rybka, W Ehmann, Christopher Ehmann, Brooke Silar, Caitlin Vajdic, Neal Shah, Leonard Tuanquin, Robert Greiner, Valerie Brown, Raymond Hohl, David Claxton, Shin Mineishi, Kentaro Minagawa, Hiroko Shike, 2022, Annals of Hematology on p. 613-620

Most-Cited Papers

O<sub>2</sub><sup>⋅−</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P. Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Shultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 487-500.e8

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Liru Wang, Bei Jia, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng, 2018, OncoImmunology

Cancer and the dopamine D<sub>2</sub> receptor: A pharmacological perspective

Jillian S. Weissenrieder, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2019, Journal of Pharmacology and Experimental Therapeutics on p. 111-126

Erratum: O<sub>2</sub> <sup>⋅−</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate (Cancer Cell (2017) 32 (2)(268) (S1535610817300624) (10.1016/j.ccell.2017.02.018))

Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P.Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Schultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 268

First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma

Bryan G. Allen, Kellie L. Bodeker, Mark C. Smith, Varun Monga, Sonia Sandhu, Raymond Hohl, Thomas Carlisle, Heather Brown, Nancy Hollenbeck, Sandy Vollstedt, Jeremy D. Greenlee, Matthew A. Howard, Kranti A. Mapuskar, Steven N. Seyedin, Joseph M. Caster, Karra A. Jones, Joseph J. Cullen, Daniel Berg, Brett A. Wagner, Garry R. Buettner, Mindi J. TenNapel, Brian J. Smith, Douglas R. Spitz, John M. Buatti, 2019, Clinical Cancer Research on p. 6590-6597

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Neil D. Palmisiano, Ming Wang, Bei Jia, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hui Zeng, Hong Zheng, 2017, Journal of Hematology and Oncology on p. 124

Brain cholesterol metabolism and Parkinson's disease

Xuemei Huang, N Sterling, Guangwei Du, Dongxiao Sun, C Stetter, Lan Kong, Yusheng Zhu, Jeffery Neighbors, Mechelle M. Lewis, H Chen, Raymond J. Hohl, Richard B. Mailman, 2019, Movement Disorders on p. 386-395

Eomes<sup>+</sup>T-bet<sup>low</sup> CD8<sup>+</sup> T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia

Bei Jia, Chenchen Zhao, Kevin L. Rakszawski, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Ming Wang, Hiroko Shike, Michael G. Bayerl, Jeffrey M. Sivik, Todd D. Schell, Joseph J. Drabick, Raymond J. Hohl, Hong Zheng, 2019, Cancer Research on p. 1635-1645

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients

Bei Jia, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Syed Rizvi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng, 2018, Blood Cancer Journal

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios A. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M. Liberati, Hartmut Goldschmidt, Andrew Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria T. Petrucci, Donna Reece, Darrell White, María Victoria Mateos, Ivan Špička, Mihaela Lazaroiu, Jesús Berdeja, Jonathan L. Kaufman, Ying Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham-Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo De Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo M. Carella, Massimo Offidani, Joan Bladé, Luis F. Casado, Heather Oakervee, Victoria Panelli, Luis Meza, Thomas Kühr, Raymond Hohl, 2022, The Lancet Haematology on p. e403-e414